<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P10392669A0935 In an attempt to reduce the incidence of NSAID-induced gastrointestinal lesions, the following approaches have been proposed: (i) use of the prostaglandin analogue misoprostol, which is an antiulcer drug which has been proven to be as effective in the prevention of NSAID-induced gastric and duodenal ulcers as in the reduction of serious upper gastrointestinal complications; (ii) histamine H2 receptor antagonists (H2 antagonists), e.g. ranitidine, cimetidine and famotidine, which are useful in the prevention of NSAID-induced duodenal ulcers during long term treatment, but not in the prevention of NSAID-induced gastric ulcers; (iii) proton pump inhibitors, e.g omeprazole, and pantoprazole, whose efficacy in preventing NSAID-associated ulcers has been recently demonstrated; and (iv) barrier agents, e.g. sucralfate, which cannot be recommended as prophylactic agents to prevent NSAID-induced gastropathy."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="927" language="x-unspecified"/><edu.cmu.tanl.type.gene _indexed="1" _id="13" _ref_sofa="1" begin="326" end="344" Gene="histamine H2 receptor"/><edu.cmu.tanl.type.gene _indexed="1" _id="18" _ref_sofa="1" begin="357" end="358" Gene="H2"/></CAS>